Retatrutide

Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, representing the most advanced incretin-based compound in metabolic research.

• Retatrutide achieves unprecedented metabolic modulation through synchronized activation of three complementary pathways, producing effects exceeding simple addition.

• Research demonstrates 24.2% weight reduction in clinical models, with 93% of subjects achieving complete normalization of liver fat content.

• Studies reveal unique metabolic reprogramming effects, preventing the adaptive thermogenesis typically seen with single-pathway interventions.

Retatrutide creates synergistic metabolic activation, comprehensive fat reduction, and sustained energy expenditure, offering researchers an unparalleled tool for metabolic investigation.

Composition: Retatrutide (10 mg) and (20 mg)